OrthoPediatrics Q4: 17% Revenue Growth to $61.6M, Sports Medicine Sales +118.5%
OrthoPediatrics posted Q4 revenue of $61.61 million, up 17% year-over-year, beating estimates by 4.05%. EPS loss narrowed to $0.26 per share versus a year-ago $0.29 gap, topping consensus by 29.7%, with sports medicine sales surging 118.5% to $1.37 million.
1. Earnings Highlights
OrthoPediatrics reported Q4 revenue of $61.61 million, a 17% increase year-over-year, surpassing consensus by 4.05%. Adjusted EPS loss narrowed to $0.26 per share from $0.29, beating estimates by 29.7%.
2. Segment Performance
Trauma and deformity sales reached $42.64 million, up 17.1% but slightly below the $43.45 million consensus, while scoliosis sales rose 12.6% to $17.6 million versus $15.17 million expected. Sports medicine sales more than doubled to $1.37 million, exceeding forecasts by over 100%.
3. Stock Reaction and Outlook
Shares have declined 3.5% over the past month despite the earnings beat, and the stock maintains a hold rating, suggesting in-line near-term performance. Investors will monitor how these results influence full-year guidance and margin expansion plans.